Summary. A new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) was administered orally to streptozotocin-diabetic rats (60mg/kg IV) for 14 days and its effect on motor nerve conduction velocity studied. The compound significantly improved motor nerve conduction velocity of diabetic rats at a minimal dose of 10mg.kg-l-day -1 (treated 28.8+0.5 versus untreated 23.2 + 4.7 m/s, p < 0.01). The sorbitol content of the sciatic nerve and red blood cells measured after 2 weeks was concomitantly reduced in ONO-2235-treated rats (sciatic nerve: 120_+13 versus 595+146nmol/g wet weight; red blood cell: 91 +21 versus 165_+39 nmol/g haemoglobin; p < 0.01 in both 20 mg. kg-1. day-l-treated versus untreated animals). These results suggest that sorbitol accumulation might contribute to the development of peripheral nerve dysfunction in acutely diabetic animals and the new aldose reductase inhibitor could be a potential drug for therapy of diabetic neuropathy.
Summary. A new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E-methyl-3-phenylpropenylidene]rhodanine
(ONO-2235) was administered orally to streptozotocin-diabetic rats (60mg/kg IV) for 14 days and its effect on motor nerve conduction velocity studied. The compound significantly improved motor nerve conduction velocity of diabetic rats at a minimal dose of 10mg.kg-l-day -1 (treated 28.8+0.5 versus untreated 23.2 + 4.7 m/s, p < 0.01). The sorbitol content of the sciatic nerve and red blood cells measured after 2 weeks was concomitantly reduced in ONO-2235-treated rats (sciatic nerve: 120_+13 versus 595+146nmol/g wet weight; red blood cell: 91 +21 versus 165_+39 nmol/g haemoglobin; p < 0.01 in both 20 mg. kg-1. day-l-treated versus untreated animals). These results suggest that sorbitol accumulation might contribute to the development of peripheral nerve dysfunction in acutely diabetic animals and the new aldose reductase inhibitor could be a potential drug for therapy of diabetic neuropathy.
Key words:
Aldose reductase inhibitor, streptozotocin-diabetic rats, sciatic nerve sorbitol, red cell sorbitol.
There have been several reports that imply the importance of polyol accumulation in peripheral nerve tissue in the pathogenesis of diabetic neuropathy [1, 2] . Furthermore, inhibitors of aldose reductase, a key enzyme for polyol synthesis, have been reported to improve the conduction abnormalities of peripheral nerves in animal experiments [3, 4] and clinical trials [5, 6] . We have developed a new and potent aldose reductase inhibitor, a rhodanine derivative, and studied its effect on peripheral nerve abnormalities in streptozotocin-diabetic rats.
Materials and Methods

Animals
Male Sprague-Dawley rats weighing approximately 250g and 8 weeks old were used for the experiment. Diabetes was induced by IV injection of streptozotocin (60mg/kg body weight) dissolved in citrate buffer (pH 4.5). All rats were kept in identical cages and had free access to laboratory chow and water.
The following treatments were started 2 weeks after the induction of diabetes: (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235), suspended in gum arabic, was given via gastric tubing at a daily dose of 10, 20 or 40 mg/kg for 2 weeks. U1-tralente insulin was injected SC at approximately 18.00 h daily for 2 weeks at doses varying between 6-18 U according to the plasma glucose level.
Analytical Methods
Motor nerve conduction velocity (MNCV) was used as a sensitive and quantitative indicator of functional change in peripheral nerves [7, 8] , although there has been dispute about its validity [9] . Weekly measurements of MNCV were performed according to the previously reported technique using the tail nerve [81. At the end of the experiments both sciatic nerves were quickly removed by incision, weighed and homogenised in 8% (w/v) HC104 (0.5ml) and centrifuged at 3 000 rev/min for t0 min. The supernatants were neutralised with 2 N KOH and their sorbitol content determined by the enzymatic method of Bergmeyer et al. [11] . At the same time blood samples were obtained and the erythrocyte sorbitol content measured according to the method of Malone et al. [12] .
Results
The body weight of streptozotocin-diabetic rats was significantly reduced 2 weeks after streptozotocin injection compared with normal rats (diabetic rats: 233 +23 g, n=33, versus normal rats: 315_+14g, n=6, p< 0.005). Plasma glucose was also significantly increased in diabetic rats (29.1 + 3.0 mmol/l, n = 33, versus 7.8 _+ 2.0mmol/l, n=6 for control rats, p<0.005). The diabetic rats were divided randomly into three groups: ONO-2235-treated, insulin-treated and untreated. The administration of ONO-2235 had no effect on body weight or plasma glucose, but daily insulin injection Results expressed as mean-+ SD; a p < 0.01 versus untreated rats caused a noticeable increase of body weight from 256 + 26 to 330 _+ 57 g and a reduction of plasma glucose from 29.5 + 3.9 to 5.1 + 2.2 mmol/1. MNCV was significantly reduced in the streptozotocin-diabetic rats (23.2 + 2.3 m/s, n = 33, versus normal rats 34.1 + 0.9 m/s, n = 6, p < 0.005). As shown in Table 1 , insulin resulted in a significant improvement of 291 MNCV after one week of treatment. In all groups treated with ONO-2235 (10, 20 and 40 mg/kg), MNCV was significantly improved compared with the untreated group on both days 7 and 14 except for the lowest dose at day 7, which could reflect a dose-dependent effect of this compound on MNCV.
The sorbitol content of sciatic nerve and red blood cells was significantly increased in the untreated diabetic rats compared with the control rats ( Table 2 ). Both insulin and ONO-2235 significantly reduced the sorbitol content of sciatic nerve. There appeared a dose-dependency in the reduction induced by ONO-2235, though no apparent difference between the reduction at 20 and 40 mg/kg suggests a limiting effect at these dosages.
Insulin treatment for 14 days completely normalized the red cell sorbitol, while ONO-2235 was surprisingly less effective. Although insulin was equally effective at reducing sorbitol levels in both sciatic nerve and red cells, ONO-2235 was relatively ineffectual in red cells, compared with its effect on sciatic nerve sorbitol levels.
To find out whether the sorbitol content of red cells reflected that of nerve tissue, the relationship between the two was analysed (Fig. 1) . Sorbitol values of red cells from all experimental rats correlated significantly to those of sciatic nerve from the same individual rats (r= 0.79, p < 0.005).
Discussion
ONO-2235 is a newly developed aldose reductase inhibitor and is structurally different from the previously reported inhibitors, alrestatin [3, 5] and sorbinil [4, 6] . The potency of this new compound in inhibiting aldose reductase appears similar to that of sorbinil [3, 4] and 50-100 times higher than alrestatin. It seems likely that ONO-2235 ameliorated peripheral nerve dysfunction of diabetic rats by reducing sorbitol accumulation in the nerve tissue, though the possibility that this compound might have effects on other metabolic pathways cannot be ruled out. In fact, several compounds appear to improve peripheral nerve function without reducing sorbitol accumulation or inhibiting aldose reductase in diabetic animals [7, 10, 13] .
The finding in this study that sorbitol levels of red cells significantly correlated with those of sciatic nerve, is in agreement with a previous observation by Malone et al. [12] and may be important clinically for the measurement of sorbitol. However, the percentage reduction of sorbitol was considerably less in red cells than in sciatic nerve at the same dosage, which could be due to a different transport rate of the compound ONO-2235 between red cells and nerve tissue. Alternatively, aldose reductase(s) and their susceptibilities to inhibitors may be different in the two tissues. Furthermore, biochemical properties of aldose reductases are not necessarily consistent in various species [14] . Therefore, it is important to study the properties of aldose reductase inhib-itors using various tissues and species, before using red cell sorbitol values to monitor nerve tissue content in clinical trials.
